QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tenax-therapeutics-expands-global-rights-to-develop-and-manufacture-oral-levosimendan-under-amended-agreement-with-orion

On September 3, 2025, Tenax Therapeutics, Inc. (the "Company") and Orion Corporation ("Orion") entered into an ...

 piper-sandler-initiates-coverage-on-tenax-therapeutics-with-overweight-rating-announces-price-target-of-20

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Overweight rating and ann...

 guggenheim-maintains-buy-on-tenax-therapeutics-lowers-price-target-to-14

Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $...

 tenax-therapeutics-q1-eps-028-misses-019-estimate

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of ...

 tenax-therapeutics-q4-2024-gaap-eps-018-beats-042-estimate

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(...

 tenax-therapeutics-announces-25m-private-placement-with-rtw-investments

Tenax Therapeutics, Inc. (NASDAQ:TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage ph...

 tenax-therapeutics-announces-fda-review-completion-of-updated-phase-3-plan-for-tnx-103-expands-level-study-enrollment-to-230-patients-with-over-95-power-level-2-global-study-to-begin-in-2025

Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage ph...

 tenax-therapeutics-appoints-thomas-a-mcgauley-as-interim-cfo-effective-december-2-2024

- SEC Filing

 tenax-therapeutics-q3-2024-gaap-eps-019-beats-139-estimate-cash-cash-equivalents-and-investments-of-983m-expected-to-provide-a-cash-runway-through-the-end-of-2027

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(...

 leerink-partners-initiates-coverage-on-tenax-therapeutics-with-outperform-rating-announces-price-target-of-16

Leerink Partners analyst David Risinger initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Outperform rating and ...

 guggenheim-initiates-coverage-on-tenax-therapeutics-with-buy-rating-announces-price-target-of-16

Guggenheim analyst Seamus Fernandez initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Buy rating and announces P...

 william-blair-initiates-coverage-on-tenax-therapeutics-with-outperform-rating

William Blair analyst Matt Phipps initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Outperform rating.

 tenax-therapeutics-q2-2024-adj-eps-183-beats-199-estimate

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(1.83) per share which beat the analyst consensus estimate of $(...

Core News & Articles
Market-Moving News for August 6th
08/06/2024 12:23:44

LUMN: 58% | Lumen Technologies shares are trading higher after the company announced it secured $5 billion in new business from...

 tenax-therapeutics-secures-100m-in-oversubscribed-private-placement-financing

The private placement was led by new investor BVF Partners LP, with participation from other new investors, including Venrock H...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION